Significant’ findings suggest potential for effective, non-toxic treatment for this aggressive childhood cancer
Dublin, Ireland: Researchers investigating new treatments for neuroblastoma – one of the most common childhood cancers – have found that a combination of two drugs made tumours disappear in mice, making it more effective than any other drugs tested in these animals.
Professor Murray Norris, deputy director of the Children’s Cancer Institute Australia for Medical Research, Sydney, Australia, told the 30th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Thursday) that the findings were unusual and highly significant. But he warned that it would be some time before the drug combination would be tested in children and, if successful, made available more widely to treat children with this disease, even though both drugs are currently undergoing clinical trial in a range of adult cancers.
Neuroblastoma is one of the most common childhood cancers and is the leading single cause of cancer deaths in children under five. It is frequently found in the adrenal glands on top of the kidneys. Despite using intensive treatment regimens, children with the most aggressive forms of neuroblastoma have less than 50% survival rates.
Prof Norris said: “To study neuroblastoma in the laboratory, we use a genetically modified neuroblastoma mouse model that closely recapitulates clinical features of the disease, and these mice spontaneously develop neuroblastomas within weeks after birth. We have found that when we combined CBL0137 and panobinostat to treat mice bearing neuroblastomas, the tumours disappeared and never came back during the entire experiment, whereas the tumours continued to grow in mice that received either no treatment or only single drug treatment.
“This is a highly significant finding as this drug combination is the most effective therapy that we have observed in this neuroblastoma mouse model. It is unusual to see this effect, especially in these mice where neuroblastoma develops within seven weeks of birth and is aggressive in nature. In fact, the CBL0137/panobinostat combination is more effective than any other current clinical chemotherapy combinations that our laboratory has tested in these mice.”
CBL0137, which belongs to a new class of drugs called curaxins, attacks the structure of cancer cells but is a safe drug that does not damage DNA in normal cells. Prof Norris and his colleagues used RNA sequencing technology that can detect drug-induced changes in tumours, to see how the combination of CBL0137 and panobinostat stopped neuroblastoma growing.
“Our results suggest that these drugs work through two different mechanisms that offer a two-pronged attack. One of these mechanisms appears to be a direct attack on the cancer cells themselves, killing them by inhibiting DNA repair; then a second mechanism is involved in inducing a robust immune response. This is very exciting and will hopefully facilitate the clinical development of effective and non-toxic therapies for childhood cancer,” he said.
“Unlike conventional chemotherapy drugs that interact with DNA, CBL0137 is non-DNA damaging and therefore is comparatively less toxic. Developing CBL0137 combination therapies has the potential to reduce acute and long-term side effects and increase the quality of life of children with cancer while extending the survival rates of these children. Another important implication is that the CBL0137/panobinostat combination can activate an immune response which may significantly boost the efficacy of immunotherapy drugs that are otherwise ineffective for neuroblastoma.”
The researchers are continuing their laboratory work to investigate further how the combination of these two drugs activates the immune response, and to test CBL0137/panobinostat with other immunotherapy drugs in mice. A phase I clinical trial of CBL0137 in children with neuroblastoma and other difficult-to-treat childhood cancers is planned to start in 2019, following the completion of a phase I clinical trial of the drug in adults with solid cancers and previously treated blood cancers. The trial of CBL0137 alone in children will need to be completed successfully before a trial testing the combination of the two drugs can be planned, which means it will be a few years before it is known whether the treatment can be used more widely.
Further lab research by Prof Norris and his colleagues also showed that CBL0137 and panobinostat slowed the growth of aggressive childhood leukaemias in mice and significantly extended survival.
In addition to approving CBL0137 for phase I clinical trials in adults, the FDA has already approved panobinostat for multiple myeloma and it is being tested in clinical trials for a range of other cancers.
Learn more: Drug combination makes cancer disappear in mice with neuroblastoma
The Latest on: Neuroblastoma
[google_news title=”” keyword=”neuroblastoma” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neuroblastoma
- Y-mAbs to Present at 2024 ASCO Annual Meetingon April 25, 2024 at 1:11 pm
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...
- Mother's portraits bring son 'back to life'on April 25, 2024 at 7:43 am
Graeme was diagnosed with the rare cancer, neuroblastoma, in 1998 and died aged just four on New Year's Eve in 1999. “There needs to be some sort of good outcome from something that’s devastating and ...
- Mum who lost son, 4, to cancer creates artwork to 'bring him back to life'on April 24, 2024 at 7:59 pm
Joanne Humphreys, 60, a professional artist and art teacher from Cheltenham, revealed that her son Graeme was diagnosed with neuroblastoma, a rare form of cancer, in January 1998 when he was just two ...
- My brave daughter, 6, beat cancer but now it’s returned and NHS won’t fund her treatment – I’m crushedon April 23, 2024 at 12:34 pm
THE family of a six-year-old girl who beat cancer need help to pay for a last-ditch treatment after it returned. Amelia Kolpa was diagnosed with rare neuroblastoma in the stomach aged two in 2020 ...
- Community Rallies to Fulfill Wishes of 5-Year-Old Battling Stage Four Neuroblastomaon April 23, 2024 at 12:29 am
Nearly one hundred thousand euros collected in a few days to fulfill all the wishes of Sara, the 5-year-old girl from Faenza suffering from stage four neuroblastoma for whom treatment has ...
- A Community Rallies to Fulfill the Wishes of a Young Girl Battling Stage IV Neuroblastomaon April 19, 2024 at 10:51 pm
Sara Cantagalli was 3 years old when she was diagnosed with stage IV neuroblastoma. Since then, she has undergone chemotherapy, but now at the age of 5, she has had to stop treatment because ...
- Mum in race against time to raise £300K to fund clinical trial that could save 2-year-old son's lifeon April 18, 2024 at 1:32 am
Adamas Jasinauskas, from Peterborough, was only 14 months old when he was diagnosed with neuroblastoma and now after a relapse and five cycles of chemotherapy his survival hopes are down to a costly c ...
- Norgine seeks approval for high-risk neuroblastoma treatmenton April 16, 2024 at 4:19 am
N orgine has sought approval for eflornithine (difluoromethylornithine [DFMO]) for the treatment of patients with high-risk neuroblastoma (HRNB). The development marks the first marketing ...
- Neuroblastoma study identifies new subgroups with distinct prognoses and potential vulnerabilities to therapieson April 9, 2024 at 7:06 am
Researchers have identified new variations in neuroblastoma that could lead to a more accurate prognosis and better-targeted treatments for this devastating childhood cancer. A study published in ...
via Bing News